At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
PBE INVESCO BIOTECHNOLOGY & GENOME ETF
Not Yet Opened 11-02 16:00:00 EST
101.13
-1.37
-1.34%
盘后101.35
+0.22+0.22%
19:30 EST
High102.86Low101.10Vol28.70K
Open102.67D1 Closing102.50Amplitude1.72%
Mkt Cap435.87MTradable Cap435.87MTotal Shares4.31M
T/O2.92MT/O Rate0.67%Tradable Shares4.31M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Vertex Pharmaceuticals Incorporated : Scotiabank Raises Target Price to $660 from $558
THOMSON REUTERS  ·  11:45
Vertex Pharmaceuticals Incorporated : Scotiabank Raises Target Price to $660 from $558
Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (VRTX) and Idexx Laboratories (IDXX)
TIPRANKS  ·  10:00
Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (VRTX) and Idexx Laboratories (IDXX)
Alyftrek Expansion Drives Vertex's International Growth
Dow Jones  ·  05:59
Alyftrek Expansion Drives Vertex's International Growth
Biogen Inc. Stock Underperforms Monday When Compared to Competitors
Dow Jones  ·  05:54
Biogen Inc. Stock Underperforms Monday When Compared to Competitors
HealthStream Q3 Revenue, Adjusted Ebitda Beat Estimates; Raises 2026 Outlook
Reuters  ·  05:38
HealthStream Q3 Revenue, Adjusted Ebitda Beat Estimates; Raises 2026 Outlook
Inspire Medical Q3 Revenue Falls, Narrows Outlook
Reuters  ·  05:37
Inspire Medical Q3 Revenue Falls, Narrows Outlook
Vertex Pharmaceuticals Raises Outlook Following Crinetics Acquisition
Dow Jones  ·  05:20
Vertex Pharmaceuticals Raises Outlook Following Crinetics Acquisition
Vertex Pharmaceuticals: Raises FY26 Combined Gaap and Non-Gaap R&D, Aipr&D, SG&a Expense Guidance to Reflect Crinetics Integration
THOMSON REUTERS  ·  05:05
Vertex Pharmaceuticals: Raises FY26 Combined Gaap and Non-Gaap R&D, Aipr&D, SG&a Expense Guidance to Reflect Crinetics Integration
Vertex Pharmaceuticals Inc: Expects Palsonify Revenue for FY26 to be $40 to $50 Million
THOMSON REUTERS  ·  05:05
Vertex Pharmaceuticals Inc: Expects Palsonify Revenue for FY26 to be $40 to $50 Million
Vertex Q3 2026 Net Income Falls 40% Year over Year to $653.6 Million
Reuters  ·  05:03
Vertex Q3 2026 Net Income Falls 40% Year over Year to $653.6 Million
Vertex Pharmaceuticals Outlook FY Revenue USD 13,150-13,250 Million VS. Ibes Estimate USD 13,245 Million
THOMSON REUTERS  ·  05:01
Vertex Pharmaceuticals Outlook FY Revenue USD 13,150-13,250 Million VS. Ibes Estimate USD 13,245 Million
Vertex Pharmaceuticals Q3 EPS USD 2.56
THOMSON REUTERS  ·  05:01
Vertex Pharmaceuticals Q3 EPS USD 2.56
Asure Software and Vertex Announce Strategic Alliance to Expand Payroll Tax Management Reach
GlobeNewswire  ·  11-02 21:01
Asure Software and Vertex Announce Strategic Alliance to Expand Payroll Tax Management Reach
Alnylam price target lowered to $323 from $429 at Canaccord
TIPRANKS  ·  11-02 20:16
Alnylam price target lowered to $323 from $429 at Canaccord
Alnylam Pharmaceuticals, Inc. : Truist Securities Cuts to Hold from Buy; Cuts Target Price to $225 from $315
THOMSON REUTERS  ·  11-02 20:06
Alnylam Pharmaceuticals, Inc. : Truist Securities Cuts to Hold from Buy; Cuts Target Price to $225 from $315
Alnylam Pharmaceuticals, Inc. : Bernstein Cuts to Market-Perform from Outperform; Cuts Target Price to $199 from $376
THOMSON REUTERS  ·  11-02 18:46
Alnylam Pharmaceuticals, Inc. : Bernstein Cuts to Market-Perform from Outperform; Cuts Target Price to $199 from $376
Truist downgrades Alnylam on less certain Amvuttra outlook
TIPRANKS  ·  11-02 18:45
Truist downgrades Alnylam on less certain Amvuttra outlook
Sino Biopharmaceutical Stock Advances 0.9% in Hong Kong, Outperforms Competitors
Dow Jones  ·  11-02 16:33
Sino Biopharmaceutical Stock Advances 0.9% in Hong Kong, Outperforms Competitors
Big Homes, Big Loans
Dow Jones  ·  10-31
Big Homes, Big Loans
Wall St Week Ahead-Midterm US Elections, Earnings, Jobs Data Loom for AI-Wary Stock Market
Reuters  ·  10-31
Wall St Week Ahead-Midterm US Elections, Earnings, Jobs Data Loom for AI-Wary Stock Market

Introduction

Company Name.
INVESCO BIOTECHNOLOGY & GENOME ETF
Affiliated Markets:
ARCA
Listing Date:
--
Main Business:
The fund generally will invest at least 90% of its total assets in securities that comprise the underlying index. The underlying index was composed of common stocks of U.S. biotechnology and genome companies. These companies are engaged principally in the research, development, manufacture and marketing and distribution of various biotechnological products, services and processes, etc. It is non-diversified.
Issue price:
--